Reboxetine – What is it for, indications and precautions
Reboxetine – What is it for, Indications and Precautions. In addition, Reboxetine is indicated for the acute treatment of severe or very severe depressive disorder and for the maintenance of clinical improvement in patients who are responsive to initial treatment. Remission of the acute phase of depressive illness is associated with an improvement in the patient’s quality of life, in terms of social adaptation. The clinical effect is usually seen after 14 days of starting treatment with Reboxetine . So, check out now Reboxetine – What is it for, Indications and Precautions.
What is Reboxetine for: Reboxetine is an antidepressant medication that has Reboxetine as its active substance. This oral medication is indicated for the treatment of depression , since its action alters the functioning of neurotransmitters, decreasing depressive symptoms.
Use in Adults: The recommended therapeutic dose for Reboxetine is 4 mg twice daily (8 mg/day) orally. After 3 weeks, this dose can be increased to 10 mg/day if clinical response is incomplete.
News of the week:
Use in Children: There are no data available on the use of Reboxetine in children.
Reboxetine (active substance of this medicine) should not be used in patients under 18 years of age. Use in Patients with Renal or Hepatic Impairment : The initial dose in patients with renal impairment or moderate to severe hepatic impairment should be 2 mg twice daily and may be increased according to patient tolerability.
Reboxetine contraindication : Reboxetine (active substance of this medicine) is contraindicated in patients who are hypersensitive to reboxetine or any other component of the formula. This medication is contraindicated for anyone under 18 years of age.
Reboxetine Side Effects: The most common include dry mouth, constipation, insomnia , sweating, tachycardia, vertigo, difficulty urinating, urinary retention, impotence . Less commonly, increased blood pressure and heart rate, agitation, extrasystoles, fatigue , nausea, sedation, drowsiness , vertigo, occur.
Precautions for Reboxetine : Due to the report of some rare cases of seizures during the clinical studies performed, the use of Reboxetine (active substance of this drug) should be accompanied by strict monitoring in the case of patients with a history of seizure disorders; drug administration should be discontinued if the patient experiences seizures .
The concomitant use of monoamine oxidase inhibitors (MAOIs) and Reboxetine should be avoided until further data are available (see item 6 – Drug Interactions). As with all antidepressants, alternating mania/hypomania occurred during clinical studies. Close supervision of bipolar patients is therefore recommended.
Patients with urinary retention and glaucoma should be closely supervised . Above the maximum recommended dose, orthostatic hypotension was more frequently observed . Particular care should be taken when administering Reboxetine (active substance of this medicinal product) concomitantly with other medicinal products with known hypotensive action .
Useful links:
Mydriasis has been reported in association with reboxetine , therefore, caution is recommended when prescribing this drug to patients with increased intraocular pressure or those at risk of acute narrow-angle glaucoma . Reboxetine (the active substance in this medicine) should only be prescribed by doctors experienced in the treatment of depression .